One of the first line treatments for MS is Interferon‐β (IFN‐β) treatment, as well as improving clinical symptoms of the disease; IFN‐β reduces inflammatory response and reduces expression of miR‐29s.229, 230. The gene discussed is IFNB1; the disease is myeloid sarcoma.